---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-020589"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:57:23.293152+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clene: CNM-Au8 shows 60% reduced death risk (HR 0.431, p=0.0002) and 28% NfL reduction in ALS trial OLE

## Summary
- Survival analysis of CNM-Au8 30 mg vs matched PRO-ACT controls up to 3.5 years: HR 0.431 (95% CI 0.276-0.672, p=0.0002).
- NfL responder subset (n=55) showed average 28% NfL reduction at Week 76 (GMR 0.72, p<0.0001), indicating decreased axonal loss.
- More than 650 patient-years of CNM-Au8 treatment exposure with no identified safety signals.
- Data presented at 2024 ENCALS meeting; includes up to 42 months survival follow-up and 76 weeks biomarker results.

## SEC filing metadata
- accession: 0001437749-24-020589
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774924020589/0001437749-24-020589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774924020589/clnn20240611_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-020589
- JSON: https://secwatch.observer/filing/0001437749-24-020589.json
- Plain text: https://secwatch.observer/filing/0001437749-24-020589.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.